SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Dr. Lal Pathlabs Ltd (LALPATHLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539524 NSE: LALPATHLAB Hospital & Healthcare Services | Small Cap | Dr. Lal Pathlabs Share Price

₹1,535.95 -24.35 (-1.56%)

As on 05-Jun'26 16:59

Dr. Lal Pathlabs Ltd (LALPATHLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539524 NSE: LALPATHLAB Hospital & Healthcare Services | Small Cap | Dr. Lal Pathlabs Share Price

₹1,535.95 -24.35 (-1.56%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹26,157 Cr.
Current Price
₹1,536
52-Week Low / High
₹1,272 / 1,771
TTM EPS
₹30.3
TTM Sales
₹2,648 Cr.
Book Value per Share
₹147.5
P/E Ratio
51.47
Lower than its 5-year historical median
Industry PE
87
Price to Book (P/B)
10.58
Lower than its 5-year historical median
Price to Sales (P/S)
9.88
Lower than its 5-year historical median
EV/EBITDA
29.22
Lower than its 5-year historical median
Dividend Yield
0.97%
Profitability Efficiency
Return on Equity (ROE)
25.99%
Outperforms industry median
Return on Capital Employed (ROCE)
31.99%
Outperforms industry median
Return on Assets (ROA)
20.54%
Operating Profit Margin
28.4%
Net Profit Margin
21.15%
Gross Profit Margin
32.1%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
10.66%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
14.61%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
43.41%
Asset Quality
Promoter Holding
53.21%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2,305 Cr.
Equity
₹167.6 Cr.
Face Value
₹10
All Time Low / High
₹348.25 / 2121.50

Dr. Lal Pathlabs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Very Good
Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Dr. Lal Pathlabs Ltd a good quality company?
Dr. Lal Pathlabs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Dr. Lal Pathlabs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Dr. Lal Pathlabs Ltd vs industry peers?
Dr. Lal Pathlabs Ltd revenue CAGR is 13.05%, compared to the industry median CAGR of 1.38%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Dr. Lal Pathlabs Ltd?
Promoters hold 53.21% of the Dr. Lal Pathlabs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Dr. Lal Pathlabs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 13.1% based on the current price.
View More

DeciZen - make an informed investing decision on Dr. Lal Pathlabs

Decision Maker
Standalone basis

1. Right Stock

10 Year X-ray Pro
Long Term Prospect

2. Right Price

Right Price
Price Chart

3. Right Time ⓘ

Right Price
#Likely Future 5 Year CAGR.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dr. Lal Pathlabs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ48.2%43.5%37.7%34.3%32.6%34.8%32.3%22.7%26.8%32%-
Value Creation
Index ⓘ		2.62.21.81.51.41.61.90.71.01.4-

Growth Parameters ⓘ
Sales ⓘ7658821,0241,1651,2741,4911,8791,7692,1252,3522,648
Sales YoY Gr.-15.2%16.1%13.8%9.3%17%26.1%-5.8%20.1%10.7%-
Adj EPS ⓘ7.69.210.111.613.116.820.917.520.829.830.3
YoY Gr.-20.9%9.5%15%12.8%28.8%24.2%-16.3%19%43.6%-
BVPS (₹) ⓘ28.934.845.554.25970.684.997.9104.8124.3147.5
Adj Net
Profit ⓘ		126153168193218280348291347499508
Cash Flow from Ops. ⓘ142167189209272373426428505540-
Debt/CF from Ops. ⓘ0000000.80.60.20-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ13.3%13.1%7.8%10.7%
Adj EPS ⓘ16.4%18%12.6%43.6%
BVPSⓘ17.6%16.1%13.6%18.6%
Share Price 12% 1.4% 15% 7.8%

Key Financial Parameters ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		31.528.724.622.622.325.125.918.419.925.422.3
Op. Profit
Mgn % ⓘ		26.426.12524.325.727.327.52627.328.428.5
Net Profit
Mgn % ⓘ		16.417.316.416.617.118.818.516.516.321.219.2
Debt to
Equity ⓘ		0000000.20.20.100
Working Cap
Days ⓘ		6666666252453638354196
Cash Conv.
Cycle ⓘ		-15-10-12-13-15-21-19-21-24-2468

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales7658821,0241,1651,2741,4911,8791,7692,1252,352
Operating Expenses ⓘ + 5646527688829461,0831,3661,3081,5441,686
Manufacturing Costs30147178205233267363380439485
Material Costs168191219255287374448390428455
Employee Cost 133147175202232257321316403458
Other Costs ⓘ 232166195220193185234224275289
Operating Profit ⓘ 202230256283328407512461581665
Operating Profit Margin (%) 26.4%26.1%25.0%24.3%25.7%27.3%27.3%26.0%27.3%28.3%
Other Income ⓘ + 222832465851534766112
Exceptional Items ⓘ 0000000000
Interest ⓘ 0111151529342921
Depreciation ⓘ 3226313668707682136134
Profit Before Tax ⓘ 192231256292303374461391483621
Tax ⓘ 66798797809411698136124
Profit After Tax 126152168195223280345292347497
PAT Margin (%) 16.4%17.3%16.4%16.8%17.5%18.8%18.4%16.5%16.3%21.2%
Adjusted EPS (₹)7.69.210.111.713.416.820.717.520.829.7
Dividend Payout Ratio (%)16.10%16.30%22.30%25.60%44.80%59.50%29%34.20%57.80%40.30%

Valuation of Dr. Lal Pathlabs - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 4795787599039831,1771,4151,6321,7502,078
Share Capital ⓘ 83838383838383838384
Reserves ⓘ 3964956758199001,0941,3311,5481,6661,994
Debt +00000026215300
Long Term Debt0000001678300
Short Term Debt000000957000
Minority Interest0000000000
Trade Payables41516277113136123140180193
Others Liabilities ⓘ 61355865200233380362375266
Total Liabilities ⓘ 5806638791,0451,2961,5462,1812,2882,3052,536

Fixed Assets

Net Fixed Assets ⓘ +1301211731732973003713611,0711,018
Gross Block3071472262624495206677361,6671,740
Accumulated Depreciation177265489152220296374596722
CWIP ⓘ 4179311914563
Investments ⓘ 741341742142531711,0621,213213416
Inventories14172728553940233332
Trade Receivables354040535064676387105
Cash Equivalents 207235307478549889543534752768
Others Assets ⓘ 117981509781758487144194
Total Assets ⓘ 5806638791,0451,2961,5462,1812,2882,3052,536

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 142167189209272373426428505540
PBT ⓘ 192152256292303374461391483621
Adjustment ⓘ 11901794659889612075
Changes in Working Capital ⓘ 6-88101337-64030-1
Tax Paid ⓘ -67-68-92-102-89-97-118-99-128-155
Cash Flow From Investing Activity ⓘ + -148-134-166-93-19-195-449-2881-293
Capex -42-49-66-39-48-35-68-38-52-52
Net Investments -111-92-118-7947-174512-2688-325
Others ⓘ 571825-1814-892174684
Cash Flow From Financing Activity ⓘ + 1-3213-54-187-136141-270-411-325
Net Proceeds from Shares ⓘ 1744400001313
Net Proceeds from Borrowing ⓘ 0000000-83-830
Interest Paid ⓘ -1-0-0-0-15-15-29-34-29-21
Dividend Paid ⓘ -15-37-31-54-153-99-116-99-199-200
Others ⓘ -01-0-0-19-22286-54-103-116
Net Cash Flow ⓘ -5136616542118-13195-78

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)32.6228.8725.1823.5323.6625.9326.6419.1920.5125.99
ROCE (%)48.1543.5337.6534.3432.634.8232.2722.7126.8331.99
Asset Turnover Ratio1.521.421.331.211.091.051.010.790.930.97
PAT to CFO Conversion(x)1.131.11.131.071.221.331.231.471.461.09
Working Capital Days
Receivable Days15.3015.5014.3014.6014.8013.9012.7013.501315
Inventory Days6.606.507.808.5011.9011.507.706.504.805.10
Payable Days79.708794.1099.90120.80121.20105.60123.50136.70149.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dr. Lal Pathlabs Ltd FAQs

The current trading price of Dr. Lal Pathlabs on 05-Jun-2026 16:59 is ₹1,536.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Dr. Lal Pathlabs stood at ₹26,156.5 Cr

The latest P/E ratio of Dr. Lal Pathlabs as of 04-Jun-2026 is 51.47.

The latest P/B ratio of Dr. Lal Pathlabs as of 04-Jun-2026 is 10.58.

The 52-week high of Dr. Lal Pathlabs is ₹1,771.3 and the 52-week low is ₹1,272.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Lal Pathlabs is ₹2,648 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Lal Pathlabs Ltd is a good quality company.

The key valuation ratios of Dr. Lal Pathlabs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Dr. Lal Pathlabs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Dr. Lal Pathlabs Ltd

Dr. Lal Pathlabs was incorporated as ‘Dr. Lal PathLabs Private Limited’, a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana (RoC) on February 14, 1995 at Delhi. Subsequently, the name of the company was changed to ‘Dr. Lal PathLabs Limited’ upon conversion of the company into a public limited company pursuant to a special resolution of the shareholders of the company dated August 7, 2015 and a fresh certificate of incorporation was issued by the RoC on August 19, 2015. The company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations.

The company is well known and widely regarded for consistently introducing pioneer tests and technologies in Indian Diagnostics Market. The company has launched multiple “Center of Excellence” in recent times focusing on various specialities such as Genevolve (Genetic Testing), L-ACE(Autoimmunity), L-CoRD (Reproductive Diagnosis) & L-CID (Infectious Diseases) defining the steps towards Medical Excellence. The company has expanded its test offering which include basic preventive health packages “SwasthFit” to most advanced investigations such as Comprehensive Genomic Profile, Myeloid testing for Haematological Malignancies & Amyloid Typing Solutions. The company is actively working to introduce the Artificial Intelligence based algorithm in multiple diagnostics areas such as Histopath & Haematology to improve the efficiency, accuracy and reproducibility of results.

Business area of the company

The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

Popular tests of the company 

  • Pregnancy Test
  • Full Body Checkups
  • Heart Test
  • Kidney Test
  • Liver Test
  • CBC Test
  • Cholesterol Test
  • HbA1c Test
  • Hepatitis B Test
  • Kidney Function Test
  • Liver Function Test
  • Sugar Test
  • Thyroid Test
  • Typhoid Test
  • Uric Acid Test
  • Vitamin B12 Test
  • Vitamin D Test
  • Allergy Test
  • Arthritis Test
  • Cancer Test
  • Bone And Joint
  • Dengue Test
  • Diabetes Test
  • Rheumatoid Test
  • Tuberculosis Test
  • Infertility Test
  • Diabetes Care
  • Anemia Test
  • GastroIntestinal
  • Autoimmune Disorders
  • Fever Test

Awards and accreditations

  • 2001: Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials.
  • 2002: Fully accredited by the College of American Pathologists’ Laboratory Accreditation Program.
  • 2008: Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category.
  • 2010: Franchisor of the Year in healthcare, at the Franchise Plus Awards.
  • 2010: Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards.
  • 2012: Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards.
  • 2012: Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare.
  • 2013: Best Diagnostic Company in India at the VC Circle Healthcare Summit.
  • 2014: Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions.
  • 2014: Received an NABL certificate of accreditation under standard ISO 15189:2012 for “Medical Laboratories - Requirements for Quality and Competence” for medical testing, for National Reference Laboratory.
  • 2015: Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the ‘Cloud’ category.
  • 2015: Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India.

Major events and milestones

  • 1949: Founded by Dr. Major S. K. Lal.
  • 1995: Company incorporated as Dr Lal PathLabs Private Ltd.
  • 2000: Dr Lal Path Labs at Hanuman Road, Delhi received NABL Accreditation.
  • 2001: Dr Lal Path Labs at Hanuman Road, Delhi received ISO 9001:2000 certification.
  • 2002: Dr Lal Path Labs at Hanuman Road, Delhi received International Accreditation from CAP.
  • 2005: onwards Investment by WestBridge Capital.
  • 2008: Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited.
  • 2010: National Reference Lab set up in Delhi.
  • 2015: Successful IPO listing in Dec 2015.
  • 2017: Introduction of Next Generation Sequencing (NGS).
  • 2017: Launch of Kolkata Reference Lab.
  • 2017: Inauguration of first international lab in Nepal.
  • 2018: Inauguration of second international lab in Bangladesh.
  • 2019: Launch of Genevolve centre of excellence for Genetic testing.
  • 2020: First COVID RT-PCR testing network in private sector in India.
  • 2021: Acquisition of Suburban Diagnostics in Mumbai.
  • 2022: Launch of Bangalore Reference Lab.
  • 2023: Launch of Mumbai Reference Lab.
  • 2025: Dr. Lal PathLabs expands genomics capabilities with Illumina's NovaSeq X Series.
  • 2025: Dr. Lal PathLabs launches test for Amyloidosis disease.
  • 2025: Dr. Lal Pathlabs pioneers AI integration in cancer diagnosis in India.
  • 2025: Dr. Lal PathLabs launches India’s first dedicated Complement Testing Laboratory.
  • 2026: Dr. Lal PathLabs sets new standard in preventive healthcare with launch of Sovaaka.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×